MediWound (MDWD) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MediWound (MDWD) has outperformed Veraxa Biotech (VRXA) over the past year, losing 26.7% versus a loss of 88.5%. Veraxa Biotech is the larger company by market cap ($169.7 million vs $165.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDWD | VRXA |
|---|---|---|
| Share price | $12.85 | $1.20 |
| Market cap | $165.90M | $169.69M |
| 1-day change | -2.28% | +11.11% |
| YTD return | -30.39% | -88.75% |
| 1-year return | -26.74% | -88.53% |
| 5-year return | -46.17% | — |
| EPS (TTM) | $-2.17 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.03 | $27.36 |
| 52-week low | $12.52 | $1.04 |
| Distance from 52-week high | -35.85% | -95.61% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +138.68% | — |
| Average volume | 84.20K | 267.22K |
| Shares outstanding | 12.91M | 141.41M |
| Employees | 121 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDWD has outperformed VRXA by 61.8 percentage points over the past year.
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Healthcare · Biotechnology · 121 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Healthcare · Biotechnology
MDWD vs VRXA FAQ
Which is bigger, MediWound or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $169.69M compared with $165.90M for MediWound (MDWD).
Which stock has performed better over the past year, MDWD or VRXA?
MDWD returned -26.74% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are MediWound and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.